U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization
  1. Regulatory Information

GUIDANCE DOCUMENT

Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization Guidance for Industry and Food and Drug Administration Staff October 2016

Final

This guidance is being distributed for comment purposes only.

Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization

Docket Number:
FDA-2016-D-0435
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health

This guidance identifies the content and format for certain labeling components for permanent, hysteroscopically-placed tubal implant devices intended for female sterilization. FDA believes this guidance will help to ensure that a woman receives and understands information regarding the benefits and risks of this type of device prior to undergoing implantation.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe FDA's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Division of Dockets Management (HFA- 305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2016-D-0435.